{"acquisitions":[],"changes":[],"country":"GB","description":"Verdiva Bio is a UK biotech developing convenient oral cardiometabolic therapies including the once-weekly oral GLP-1 ecnoglutide. Patients with obesity and related cardiometabolic disease are the eventual buyers. The company emerged from stealth in 2025 backed by Forbion and other life-sciences VCs.","domain":"verdiva.bio","employees":null,"founded":2024,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":51.515066,"lng":-0.142502,"location":"London, UK","multiples":[],"name":"Verdiva Bio","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":411000000,"connectionsAmong":[],"currency":"USD","date":"2025-01-09","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"verdiva-bio-2025-01-09-series-a","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-14","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"verdiva-bio","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-14","status":"attributed","url":null},{"fact":"existence","publisher":"verdiva.bio","retrievedAt":"2026-05-14","status":"self-reported","url":"https://verdiva.bio"},{"fact":"description","publisher":"verdiva.bio","retrievedAt":"2026-05-14","status":"self-reported","url":"https://verdiva.bio"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":411000000,"traction":[],"updatedAt":"2026-05-14","valuations":[]}